Today: 14 May 2026
Brent crude price jumps near $70 as Iran risk lifts oil despite big U.S. stock build
11 February 2026
2 mins read

Brent crude price jumps near $70 as Iran risk lifts oil despite big U.S. stock build

London, Feb 11, 2026, 17:42 GMT — Regular session

  • Brent jumped close to 2%, trading around $70. WTI climbed as well.
  • U.S. crude inventories climbed by 8.5 million barrels last week, according to EIA data.
  • Traders are watching for the IEA’s upcoming oil market report on Feb. 12, with OPEC+ production discussions set for March 1.

Brent crude futures climbed almost 2% on Wednesday, slipping back toward $70 a barrel as fresh U.S.-Iran tensions took precedence over a notable jump in U.S. crude inventories. Brent added $1.22, or 1.77%, to reach $70.02 by 1647 GMT. U.S. West Texas Intermediate crude moved up $1.21, or 1.89%, to $65.17.

The market is wrestling with what’s driving prices at this point—physical barrels moving or fresh headlines from the Gulf. A stretch of quiet trading can erase the risk premium in a hurry. Then, a day like this, and it snaps right back.

U.S. President Donald Trump on Tuesday floated the idea of deploying a second aircraft carrier to the Middle East if talks with Iran fail to produce an agreement, even as both sides readied for negotiations. “No signs, at least for now, of escalation,” wrote Tamas Varga of PVM Oil Associates. UBS’s Giovanni Staunovo pointed out that “no supply disruption so far” has occurred. Reuters

Oil found some footing on talk that Washington might crack down harder on tankers carrying Iranian crude—heightening worries about possible reprisals near crucial shipping lanes. Traders have been quick to react to anything touching the Strait of Hormuz, the narrow channel that carries a hefty chunk of global seaborne oil.

On the supply side, fresh weekly numbers from the U.S. Energy Information Administration indicate the domestic crude market remains well supplied. For the week ending Feb. 6, commercial crude stocks (excluding the SPR) climbed by 8.5 million barrels, reaching 428.8 million. Gasoline added 1.2 million barrels. Distillate inventories moved the other way, dropping by 2.7 million barrels.

Traders went into the session expecting yet another build in inventories—just not one of this size. That headline number managed to keep the rally in check, even as stocks climbed. “Oil retains a bullish tail-risk bid,” LSEG analysts said. Vortexa’s Xavier Tang highlighted stronger demand out of India, while ANZ analysts noted that second-carrier reports have pushed some risk premium back into prices. Dawn

OPEC has given the market updated figures on the ongoing supply tug-of-war. In its latest monthly release, the cartel projected that demand for OPEC+ crude will slip by 400,000 barrels a day during the second quarter, hitting 42.20 million bpd. Eight OPEC+ states are scheduled to gather on March 1 to weigh whether to green-light more production in April. (OPEC+ groups OPEC with Russia and a handful of additional partners.)

OPEC pointed to a softer dollar boosting demand, as oil priced in greenbacks gets less expensive for buyers holding other currencies. According to the report, the group’s output slipped to 42.45 million bpd in January, a 439,000 bpd decrease from December. Kazakhstan accounted for the largest share of that decline.

Oil traders are watching for the International Energy Agency’s monthly Oil Market Report on Feb. 12—a release known to jolt forecasts for supply-demand balances and inventories ahead of the next quarter.

Brent prices clawed back some ground Wednesday, rebounding from Tuesday’s closing level. The ICE Brent contract wrapped up Feb. 10 at $68.80 per barrel, following a volatile stretch that kept traders whipsawed around the $70 mark.

The downside’s clear enough. Should U.S.-Iran talks calm down, or if supply keeps moving without hiccups, then what’s left is a market looking at rising U.S. stockpiles and OPEC+ still locked in talks about the timing for bringing more barrels online.

Eyes turn to Thursday’s IEA report, while the market also waits for the U.S. EIA’s weekly petroleum numbers due Feb. 19 and a firm schedule for renewed U.S.-Iran negotiations.

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
Kroger stock edges higher after CEO shake-up as investors sift pay and next earnings call
Previous Story

Kroger stock edges higher after CEO shake-up as investors sift pay and next earnings call

Marsh stock price (MRSH) dips as bond-sale filing lands and AI fears linger
Next Story

Marsh stock price (MRSH) dips as bond-sale filing lands and AI fears linger

Go toTop